A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance

Blood

Volumn 121, Issue 17, 2013, Pages 3459-3468

  Santoro, Fabio ^a   Botrugno, Oronza A ^a   Dal Zuffo, Roberto ^a   Pallavicini, Isabella ^a   Matthews, Geoffrey M ^b   Cluse, Leonie ^b   Barozzi, Iros ^a   Senese, Silvia ^a   Fornasari, Lorenzo ^a   Moretti, Simona ^a   Altucci, Lucia ^c   Pelicci, Pier Giuseppe ^a,d   Chiocca, Susanna ^a   Johnstone, Ricky W ^b,e   Minucci, Saverio ^a,d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; PROTEIN P53; SHORT HAIRPIN RNA; VALPROIC ACID; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; FETUS; FETUS LIVER; GENE OVEREXPRESSION; GENE SILENCING; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL; HISTONE ACETYLATION; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RNA ANALYSIS; SHORT COURSE THERAPY; STEM CELL SELF-RENEWAL; TREATMENT DURATION; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; GENETICS; MALE; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRANSGENIC MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FLOW CYTOMETRY; GENOMIC INSTABILITY; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VALPROIC ACID;

MLCS; MLOWN;

EID: 84879341188     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-461988     Document Type: Article

References (43)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-692.
2. Botrugno OA, Santoro F, Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett. 2009;280(2):134-144.
3. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009; 10(1):32-42.
4. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008;9(3):206-218.
5. Haberland M, Johnson A, Mokalled MH, Montgomery RL, Olson EN. Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci USA. 2009;106(19): 7751-7755.
6. Wilting RH, Yanover E, Heideman MR, et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 2010;29(15):2586-2597.
7. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769-784.
8. Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res. 2010;62(1):18-34.
9. de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10(11):775-783.
10. Lallemand-Breitenbach V, Zhu J, Kogan S, Chen Z, de Thé H. Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia. Nat Rev Cancer. 2005;5(10):821-827.
11. Welch JS, Yuan W, Ley TJ. PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice. J Clin Invest. 2011;121(4):1636-1645.
12. Westervelt P, Lane AA, Pollock JL, et al. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood. 2003;102(5):1857-1865.
13. Morey L, Brenner C, Fazi F, et al. MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks. Mol Cell Biol. 2008;28(19):5912-5923.
14. Insinga A, Monestiroli S, Ronzoni S, et al. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 2004;23(5):1144-1154.
15. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318(6046): 533-538.
16. Minucci S, Monestiroli S, Giavara S, et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood. 2002;100(8):2989-2995.
17. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet. 2005;37(11): 1289-1295.
18. Whitecross KF, Alsop AE, Cluse LA, et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood. 2009; 113(9):1982-1991.
19. Michalova J, Savvulidi F, Sefc L, Faltusova K, Forgacova K, Necas E. Hematopoietic stem cells survive circulation arrest and reconstitute hematopoiesis in myeloablated mice. Biol Blood Marrow Transplant. 2011;17(9):1273-1281.
20. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002; 296(5567):550-553.
21. Vert JP, Foveau N, Lajaunie C, Vandenbrouck Y. An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics. 2006; 7:520.
22. Echeverri CJ, Beachy PA, Baum B, et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods. 2006; 3(10):777-779.
23. Ronzoni S, Faretta M, Ballarini M, Pelicci P, Minucci S. New method to detect histone acetylation levels by flow cytometry. Cytometry A. 2005;66(1):52-61.
24. Leiva M, Moretti S, Soilihi H, et al. Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia. 2012;26(7): 1630-1637.
25. Lagger G, O’Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 2002;21(11):2672-2681.
26. Lee AY, Paweletz CP, Pollock RM, et al. Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry. J Proteome Res. 2008;7(12): 5177-5186.
27. Payton JE, Grieselhuber NR, Chang LW, et al. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest. 2009;119(6): 1714-1726.
28. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-221.
29. Wiegmans AP, Alsop AE, Bots M, et al. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res. 2011;71(10): 3603-3615.
30. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2005;11(1):71-76.
31. Zhong S, Hu P, Ye TZ, Stan R, Ellis NA, Pandolfi PP. A role for PML and the nuclear body in genomic stability. Oncogene. 1999;18(56): 7941-7947.
32. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6(1):38-51.
33. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase inhibitors and genomic instability. Cancer Lett. 2009;274(2): 169-176.
34. Robert T, Vanoli F, Chiolo I, et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature. 2011; 471(7336):74-79.
35. Occhionorelli M, Santoro F, Pallavicini I, et al. The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha. Leukemia. 2011;25(5):814-820.
36. Zimonjic DB, Pollock JL, Westervelt P, Popescu NC, Ley TJ. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci USA. 2000;97(24): 13306-13311.
37. Guibal FC, Alberich-Jorda M, Hirai H, et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood. 2009;114(27):5415-5425.
38. Wojiski S, Guibal FC, Kindler T, et al. PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia. 2009;23(8): 1462-1471.
39. Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011;29(3):255-265.
40. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008;409(2):581-589.
41. Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005; 436(7051):660-665.
42. Di Micco R, Sulli G, Dobreva M, et al. Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol. 2011;13(3): 292-302.
43. Reimann M, Lee S, Loddenkemper C, et al. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell. 2010;17(3): 262-272.